Updated Jul 16, 2026 · Last SEC filing 2026-07-01
Akebia Therapeutics, Inc. (AKBA) has filed 7 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-01. 3 Form 8-K material event filings were reported by AKBA in the last 90 days. 1 Form 144 notices of proposed sale were filed for AKBA stock. InsiderAlpha tracks every AKBA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001517022 |
|---|
| Form 4 filings (90d) | 7 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-07-01 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Ostrowski Erik | SVP, CFO, CBO & Treasurer | S — Open-market sale | 56.0K | $1.11 | $62K | SEC | |
| ROGERS MICHAEL W | Insider | A — Grant or award | 35.7K | $0.00 | — | SEC | |
| Wolf Myles | Insider | A — Grant or award | 35.7K | $0.00 | — | SEC | |
| FRIESON RON | Insider | A — Grant or award | 35.7K | $0.00 | — | SEC | |
| ADAMS ADRIAN | Insider | A — Grant or award | 35.7K | $0.00 | — | SEC | |
| Smith Cynthia | Insider | A — Grant or award | 35.7K | $0.00 | — | SEC | |
| ZUMWALT LEANNE M | Insider | A — Grant or award | 35.7K | $0.00 | — | SEC | |
| Butler John P. | CEO and President | P — Open-market purchase | 69.3K | $1.25 | $87K | SEC | |
| Butler John P. | CEO and President | S — Open-market sale [10b5-1] | 46.7K | $1.39 | $65K | SEC | |
| Malabre Richard C | SVP, Chief Accounting Officer | S — Open-market sale [10b5-1] | 36.1K | $1.39 | $50K | SEC | |
| Burke Steven Keith | SVP, Chief Medical Officer | S — Open-market sale [10b5-1] | 25.4K | $1.39 | $35K | SEC | |
| Malabre Richard C | SVP, Chief Accounting Officer | S — Open-market sale [10b5-1] | 13.4K | $1.39 | $19K | SEC | |
| Grund Nicholas | Chief Commercial Officer | S — Open-market sale [10b5-1] | 53.6K | $1.39 | $74K | SEC | |
| Grund Nicholas | Chief Commercial Officer | S — Open-market sale [10b5-1] | 31.2K | $1.39 | $43K | SEC | |
| Butler John P. | CEO and President | S — Open-market sale [10b5-1] | 96.1K | $1.39 | $134K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Akebia Therapeutics, Inc. (AKBA). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| ROGERS MICHAEL W | 2 | — |
| FRIESON RON | 2 | — |
| ZUMWALT LEANNE M | 2 | — |
| Smith Cynthia | 2 | — |
| ADAMS ADRIAN | 2 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AKBA insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live AKBA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.